Search

Atibuclimab

Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

Erythropoietin

It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. … The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504].

Hematin

Glucagon

[L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]

Efalizumab

The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]

Sulpiride

[A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

Promethazine

[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]

Aminophenazone

The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]

Asenapine

FDA approved on August 13, 2009.

Tucatinib

It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.